2月27日 - ** Zevra Therapeutics ZVRA.O股价上涨5.14%至7.77美元
** Zevra称 (link)，该公司已达成协议，将以1.5亿美元的价格出售其罕见儿科疾病优先审评券$(PRV.UK)$
** 在其药物 Miplyffa 获得批准后，美国 FDA 于 2024 年 9 月授予该公司 PRV。
** Miplyffa 用于与 co 公司的另一种遗传性疾病药物 miglustat 联用，治疗 2 岁及以上成人和儿童患者遗传的罕见神经系统疾病。
** PRV 持有者可享受 FDA 对任何疾病的新药申请进行的为期 6 个月的快速审查
** ZVRA 年度累计下跌 7.19
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.